CA3166495A1 - Insulin derivative - Google Patents

Insulin derivative

Info

Publication number
CA3166495A1
CA3166495A1 CA3166495A CA3166495A CA3166495A1 CA 3166495 A1 CA3166495 A1 CA 3166495A1 CA 3166495 A CA3166495 A CA 3166495A CA 3166495 A CA3166495 A CA 3166495A CA 3166495 A1 CA3166495 A1 CA 3166495A1
Authority
CA
Canada
Prior art keywords
human insulin
desb30 human
yglu
insulin
eicosanedioyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3166495A
Other languages
English (en)
French (fr)
Inventor
Zhongru Gan
Wei Chen
Yining Zhang
Fangkai XUE
Lingyu CAI
Jianghong NIU
Bin MU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gan and Lee Pharmaceuticals Co Ltd
Original Assignee
Gan and Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan and Lee Pharmaceuticals Co Ltd filed Critical Gan and Lee Pharmaceuticals Co Ltd
Publication of CA3166495A1 publication Critical patent/CA3166495A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3166495A 2019-12-30 2020-12-29 Insulin derivative Pending CA3166495A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911398378 2019-12-30
CN201911398378.0 2019-12-30
CN202011057926.6 2020-09-29
CN202011057926 2020-09-29
PCT/CN2020/141018 WO2021136293A1 (zh) 2019-12-30 2020-12-29 胰岛素衍生物

Publications (1)

Publication Number Publication Date
CA3166495A1 true CA3166495A1 (en) 2021-07-08

Family

ID=76687317

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3166495A Pending CA3166495A1 (en) 2019-12-30 2020-12-29 Insulin derivative
CA3166494A Pending CA3166494A1 (en) 2019-12-30 2020-12-29 Insulin derivative

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3166494A Pending CA3166494A1 (en) 2019-12-30 2020-12-29 Insulin derivative

Country Status (10)

Country Link
US (5) US20240025957A1 (enExample)
EP (3) EP4086278A4 (enExample)
JP (3) JP2023510219A (enExample)
KR (2) KR20220119730A (enExample)
CN (12) CN118754967A (enExample)
AU (2) AU2020418205A1 (enExample)
BR (2) BR112022013150A2 (enExample)
CA (2) CA3166495A1 (enExample)
MX (2) MX2022008130A (enExample)
WO (3) WO2021136293A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118754967A (zh) * 2019-12-30 2024-10-11 甘李药业股份有限公司 胰岛素衍生物
EP4086277A4 (en) * 2019-12-30 2024-02-14 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN115385843A (zh) * 2021-05-24 2022-11-25 广东东阳光药业有限公司 一种新型的酰化胰岛素类似物
AU2022300061A1 (en) * 2021-06-25 2024-02-01 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin-containing pharmaceutical composition
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
US20250340610A1 (en) * 2022-01-28 2025-11-06 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途
CN121219311A (zh) * 2023-05-24 2025-12-26 联邦生物科技(珠海横琴)有限公司 一种胰岛素衍生物及其应用
CN116327890B (zh) * 2023-05-29 2023-12-08 北京先为达生物科技有限公司 口服递送的组合物及其应用
CN116789801B (zh) * 2023-08-21 2023-11-14 南京赛诺生物技术有限公司 新型胰岛素衍生物及其用途
WO2025077751A1 (zh) * 2023-10-09 2025-04-17 甘李药业股份有限公司 Glp-1肽组合物及其用途
WO2025098457A1 (zh) * 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
WO2025098502A1 (zh) * 2023-11-08 2025-05-15 甘李药业股份有限公司 包含胰岛素衍生物的药物组合物的治疗用途
WO2025228255A1 (zh) * 2024-04-28 2025-11-06 正大天晴药业集团股份有限公司 酰化人胰岛素类似物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
DE602007009496D1 (de) * 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
EP2015770B1 (en) * 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
JP5688969B2 (ja) 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
JP5721432B2 (ja) * 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
US9150633B2 (en) 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
EP2552951A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
CN103596584B (zh) * 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
KR20140104994A (ko) 2011-12-15 2014-08-29 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 인간 인슐린 유사체 및 이의 아실화 유도체
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN105820233B (zh) 2015-01-04 2021-06-15 甘李药业股份有限公司 一种胰岛素衍生物的制备方法
WO2016119854A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
ES2908373T3 (es) * 2015-08-25 2022-04-28 Novo Nordisk As Nuevos derivados de insulina y los usos médicos de los mismos
PL3341991T3 (pl) * 2015-08-27 2020-11-30 Haldor Topsøe A/S Materiał aktywny litowej elektrody dodatniej o wysokiej gęstości nasypowej z usadem, półprodukt i sposób wytwarzania
WO2018024186A1 (zh) 2016-08-02 2018-02-08 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
CN118754967A (zh) * 2019-12-30 2024-10-11 甘李药业股份有限公司 胰岛素衍生物
EP4086277A4 (en) * 2019-12-30 2024-02-14 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound
US20250340610A1 (en) * 2022-01-28 2025-11-06 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin

Also Published As

Publication number Publication date
CN114901682A (zh) 2022-08-12
CN118206632A (zh) 2024-06-18
MX2022008130A (es) 2022-10-03
US20250032589A1 (en) 2025-01-30
CN114901683A (zh) 2022-08-12
US20250228919A1 (en) 2025-07-17
JP2023510219A (ja) 2023-03-13
BR112022013150A2 (pt) 2023-02-28
CA3166494A1 (en) 2021-07-08
CN114901682B (zh) 2024-04-16
BR112022013009A2 (pt) 2022-09-06
EP4086279A1 (en) 2022-11-09
US20240239862A1 (en) 2024-07-18
WO2021136296A1 (zh) 2021-07-08
EP4086278A1 (en) 2022-11-09
AU2020418205A1 (en) 2022-08-04
CN114901681B (zh) 2024-04-09
CN114901681A (zh) 2022-08-12
WO2021136302A1 (zh) 2021-07-08
KR20220121833A (ko) 2022-09-01
EP4086280A1 (en) 2022-11-09
CN118754967A (zh) 2024-10-11
CN118598978A (zh) 2024-09-06
CN114901683B (zh) 2024-09-13
US20240025957A1 (en) 2024-01-25
CN118420743A (zh) 2024-08-02
AU2020417892A1 (en) 2022-08-25
JP2023510206A (ja) 2023-03-13
WO2021136293A1 (zh) 2021-07-08
CN118480114A (zh) 2024-08-13
KR20220119730A (ko) 2022-08-30
EP4086280A4 (en) 2024-05-29
US12576136B2 (en) 2026-03-17
EP4086279A4 (en) 2024-08-07
CN118420744A (zh) 2024-08-02
JP2025161829A (ja) 2025-10-24
MX2022008174A (es) 2022-08-02
US20230126068A1 (en) 2023-04-27
CN118666989A (zh) 2024-09-20
EP4086278A4 (en) 2024-08-07
CN118772259A (zh) 2024-10-15
CN118894922A (zh) 2024-11-05

Similar Documents

Publication Publication Date Title
US20250228919A1 (en) Insulin Derivative
JP2023510206A5 (enExample)
JP2023510219A5 (enExample)
JP2023510218A (ja) 長時間作用型ｇｌｐ－１化合物
US20250262282A1 (en) Acylated Insulin-Containing Pharmaceutical Composition
US20250340610A1 (en) Acylated insulin
EA050726B1 (ru) Производное инсулина
EA050813B1 (ru) Производное инсулина
HK40109784A (zh) 胰岛素衍生物
HK40070502A (zh) 胰岛素衍生物
HK40070502B (zh) 胰岛素衍生物
HK40103864A (en) Acylated insulin-containing pharmaceutical composition

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220630

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241108

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241219

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250310

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250311

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250714

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250714

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20250731

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20250731

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250731

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250923

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250923

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250923